The UK government has published a new five year plan aimed at tackling antimicrobial resistance (AMR), including a new NHS reimbursement scheme backed by NICE to encourage pharma to develop
While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug has received a label extension from the European Commission allowing it to be used in you
Vertex is to file its two latest cystic fibrosis drugs with Scotland’s drug cost watchdog in a bid for NHS reimbursement – but an ongoing row over price in England is still unresolved.
NICE has published new standards setting out the requirements needed to develop digital health technologies for the NHS and speed up uptake of products like healthcare apps and wearable devices.
NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for m